from Today's Healthcare News -- ScienceDaily http://ift.tt/1PY2Fk9
Our mission is to advice, and to make the people of the world healthier through the power of information.
Investigation casts doubt over trial used to support top-selling anti-clotting drug
An investigation raises new concerns about the top-selling anti-clotting drug, rivaroxaban (Xarelto). The trial compared rivaroxaban with the older anti-clotting drug warfarin for preventing strokes in patients with irregular heartbeat (atrial fibrillation).
from Today's Healthcare News -- ScienceDaily http://ift.tt/1PY2Fk9
from Today's Healthcare News -- ScienceDaily http://ift.tt/1PY2Fk9
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment